{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Immuron Limited"},"Symbol":{"label":"Symbol","value":"IMRN"},"Address":{"label":"Address","value":"CHAPMAN STREET,UNIT 10, 25-37, MELBOURNE, 3130, Australia"},"Phone":{"label":"Phone","value":"+61 398245254"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Australia and South Pacific"},"CompanyDescription":{"label":"Company Description","value":"Immuron Limited is commercializing and developing a novel class of specifically targeted polyclonal antibodies which are delivered within the gastrointestinal tract and do not cross into the bloodstream. Products in clinical development have the potential to transform standard of care for moderate to severe Campylobacteriosis, Clostridioides difficile infections, Enterotoxigenic Escherichia coli (ETEC) infections and Traveler's Diarrhea. Immuron markets Travelan速 in Australia, Canada and the U.S. In Australia, Travelan速 is indicated to reduce the risk of travelers' diarrhea and to reduce the risk of minor gastro-intestinal disorders. In Canada, Travelan速 is indicated to reduce the risk of travelers' diarrhea. In the U.S, Travelan速 is a dietary supplement for digestive tract protection."},"CompanyUrl":{"label":"Company Url","value":"https://www.immuron.com.au"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jerry Kanellos","title":"Chief Operating & Scientific Officer"},{"name":"Joanne Casey","title":"Manager-Research & Development"},{"name":"Steven Lydeamore","title":"Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}